Patient-derived precision cut tissue slices from primary liver cancer as a potential platform for preclinical drug testing.

ABSTRACT:

Background

The exploitation of anti-tumour immunity, harnessed through immunomodulatory therapies, has fundamentally changed the treatment of primary liver cancer (PLC). However, this has posed significant challenges in preclinical research. Novel immunologically relevant models for PLC are urgently required to improve the translation from bench to bedside and back, explore and predict effective combinatorial therapies, aid novel drug discovery and develop personalised treatment modalities.

Methods

We used human precision-cut tissue slices (PCTS) derived from resected tumours to create a patient-specific immunocompetent disease model that captures the multifaceted and intricate heterogeneity of the tumour and the tumour microenvironment. Tissue architecture, tumour viability

SUBMITTER: Jagatia R 

PROVIDER: S-EPMC10667128 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature